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Abstract
A simple, rapid, sensitive reversed-phase high-performance liquid chromatography method was developed and validated for
simultaneous measurement of albendazole and praziquantel with an internal standard, simvastatin, at single wavelength of 225 nm.
Chromatographic separation was performed on an Enable C18 column (250 mm ×  4.6 mm, 5 m: Spinco Biotech Pvt Ltd) and a
mobile phase consisting of acetonitrile:water (60:40, v/v) with 10% orthophosphoric acid to adjust the pH to 3.2, at a flow rate
of 1.0 ml/min. The calibration curve was linear (r2 ≥  0.999) over the concentration range 0.05–8.0 g/ml. The concentrations of
simvastatin was 1.0 g/ml. The limit of quantification was 0.05 g/ml for both albendazole and praziquantel. No interference
was found by the excipients in the synthetic mixture. The proposed methods were validated as per International Conference on
Harmonisation guidelines for linearity, accuracy, precision and robustness for estimation of albendazole and praziquantel in bulk
and in a synthetic mixture, and the results were found to be satisfactory.
© 2013 Taibah University. Production and hosting by Elsevier B.V. All rights reserved.
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1.  Introduction
Neurocysticercosis is the commonest helminthic dis-
ease of the nervous system and is considered a serious
public health problem in developing countries of Latin
America, Asia, and Africa [1–3]. Although the treatment
of neurocysticercosis is restricted to palliative measures,
it has advanced over the past 20 years with the use of
praziquantel and albendazole, which are effective against
the cystic larvae [2,4]. Albendazole is more effective Peer review under responsibility of Taibah University.
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than praziquantel, but cysts persist in some patients even
after repeated use of albendazole [2]. For these cases,
alternative treatment schedules such as simultaneous use
of praziquantel and albendazole have been evaluated
[4,5]. The combination of praziquantel with albendazole
has also been extensively used in human hydatid dis-
ease [6–9]. Albendazole is extensively metabolized to
its active metabolite albendazole sulfoxide, which is fur-
ther metabolized to the inactive albendazole sulfone [10].
Because of this extensive metabolism, plasma concen-
trations of albendazole are usually low, and pharmacoki-
netics are studied by measuring the sulfoxide and sulfone
concentrations [11–15]. Praziquantel is metabolized to
several hydroxylated metabolites [16–18], mainly trans-
4-hydroxypraziquantel, an active metabolite [19].
In order to evaluate the kinetics of albendazole and
praziquantel, selective, sensitive, reproducible analyt-
ical methods are required for their quantification in
plasma samples as well as for their metabolites. High-
performance liquid chromatography (HPLC) [20–29]
and capillary electrophoresis [30,31] have been used,
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Fig. 1. Chemical structure of albendazole.
nd the coupling of mass spectrometry to liquid chro-
atography (LC–MS and LC–MS–MS) has brought
ew insight into quantitative bioanalysis. Use of these
echniques for the analysis of albendazole metabolites,
raziquantel and trans-4-hydroxypraziquantel has been
escribed only for isolated drugs. Bonato et al. [32]
nd Chen et al. [33] reported the use of LC–MS–MS
or two methods, with quantification limits for alben-
azole sulfoxide of 5.0 and 4.0 g/ml, respectively, and
 quantification limit of 0.5 g/ml for albendazole sul-
one. LC–MS–MS was used only for qualitative analysis
f praziquantel metabolites [16,34].
The aim of this work was to develop an HPLC method
or simultaneous estimation of albendazole and prazi-
uantel in bulk and in the synthetic mixture. The method
as validated according to the International Conference
n Harmonisation guidelines.
.  Materials  and  methods
.1.  Chemicals  and  reagents
Albendazole (Fig. 1) was obtained from Mercury
harmaceutical Ltd, Vadodara, Gujarat, India, prazi-
uantel (Fig. 2) from Micro Labs Ltd, Goa, India, and
imvastatin (internal standard) (Fig. 3) from Dr Reddy’s
ab, Hyderabad, India. Acetonitrile, methanol and water
f HPLC grade were used. All the other reagents (includ-
ng 10% ortho-phosphoric acid) were of analytical grade.
.2.  Chromatographic  conditionsThe high-performance liquid chromatograph (Shi-
adzu, Kyoto, Japan) was composed of an LC-20AT
N
N
O
O
Fig. 2. Chemical structure of praziquantel.Fig. 3. Chemical structure of simvastatin (IS).
Prominence solvent delivery module, a manual rheo-
dyne injector with a 20-l fixed loop and a SPD-20A
Prominence ultraviolet–visible detector. Separation was
performed on an Enable C18 G column (particle
size 5 m; 250 mm ×  4.6 mm) preceded by an ODS
guard column (10 m, 10 mm ×  5 mm) at ambient
temperature. Data were acquired on a Spinchrom
Chromatographic Station® CFR Version 2.4.0.195
(Spinchrom Pvt. Ltd, Chennai, India). The mobile phase
consisted of acetonitrile:water in a ratio of 60:40, the pH
was adjusted to 3.2 with ortho-phosphoric acid, and the
flow rate was 1.0 ml/min. Mo was vacuum filtered and
degassed through 0.2 m pore polymeric PTFE filters.
2.3.  Method
2.3.1.  Preparation  of  standard  stock  solutions
A sample of 25 mg of each drug is weighed and trans-
ferred to a 25-ml volumetric flask; 15 ml of methanol are
added, and the solution is sonicated for 15 min. The vol-
ume is made up to the mark with methanol to obtain
a stock solution of 1000 g/ml. Simvastatin is also pre-
pared in the diluent to obtain a working standard solution
of 1000 g/ml.
2.3.2.  Preparation  of  working  standard  solutions
From the standard stock solutions, 2.5 ml are with-
drawn and transferred to 25-ml volumetric flasks, and
the volume is made up to the mark with diluent to obtain
working standard solutions of 100 g/ml. The working
standard solution of simvastatin is diluted to a final solu-
tion of 10 g/ml.
2.4.  ValidationThe method was validated by evaluating recovery,
linearity, precision, accuracy, quantification limit and
stability. Coefficients of variation and relative errors <2%
were considered acceptable [35,36].
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2.4.1.  Linearity
Linearity was tested at concentrations of 8, 7, 6, 5,
4, 3, 2, 1, 0.5 and 0.05 g/ml for albendazole and praz-
iquantel with a fixed concentration of 1 g/ml diluted
from 10 g/ml of the working standard solution. The
calibration curve was constructed and its coefficient
of determination (r2) determined. The calibration plot
(peak area ratio of albendazole and praziquantel to
internal standard versus albendazole and praziquan-
tel concentration) was generated by replicate analysis
(n = 10) at all concentrations, and the linear relation
was evaluated by the least-squares method in Microsoft
Excel®. For minimum error, 10 concentrations were
tested, giving a wide range of linearity.
2.4.2. Accuracy
The accuracy of the method was determined by repli-
cate analyses with two standard addition methods at six
concentrations, the first at 80%, 100% and 120% and
the second at 50%, 100% and 150%. Comparison of the
difference between the spiked value (theoretical value)
and that found gave the accuracy.
2.4.3. Precision
The precision of the method, measured as within-day
repeatability, was determined by replicate analyses of
three sets of samples spiked with three concentrations
of albendazole and praziquantel (0.05, 1 and 8 g/ml)
and a fixed concentration of internal standard (1 g/ml).
The reproducibility (day-to-day variation) of the method
was validated with the same concentration range, but
with only a single determination of each concentration
on three days. The relative standard deviation was calcu-
lated from the ratio of the standard deviation to the mean
and expressed as a percentage.
2.4.4.  Speciﬁcity
Specificity was measured by analysing the standard
solutions in the presence of an excipient (talc) to
determine any interference in the percentage recovery.
Standard solutions containing 10 mg of each drug were
spiked with 50% (5 mg), 100% (10 mg) or 150% (15 mg)
of talc and analyzed for albendazole and praziquantel
recovery by HPLC with a fixed concentration of internal
standard (1 g/ml). The acceptable level of interference
was <0.5%.2.4.5.  Robustness
The robustness of the method for determining alben-
dazole and praziquantel was evaluated by varying the
flow rate, pH and mobile phase ratio. The percentageFig. 4. Calibration curve of praziquantel.
recovery and relative standard deviation were recorded
for both drugs.
3.  Results  and  discussion
3.1.  Calibration  curve
The coefficient correlation r, slope and intercept were
0.999, 1.064 and 0.358 for albendazole and 0.999, 0.169
and 0.060 for praziquantel with ultraviolet detection
(Fig. 6) with absorbance maxima set at 225 nm. The
retention times were 4.533 for albendazole, 6.39 for praz-
iquantel and 7.8 for the internal standard (Fig. 7). Linear
regression of data from the calibration curve indicated
a linear response over the concentration range of both
drugs. The curve can therefore be used for determination
of albendazole and praziquantel in synthetic mixtures.
3.2.  Validation
3.2.1.  Linearity
The coefficient of determination (r2) for both alben-
dazole and praziquantel was 0.999 (Tables 1 and 2 and
Figs. 4 and 5).
3.2.2.  Limit  of  detection  and  limit  of  quantiﬁcation
The limit of detection and the limit of quantification
were determined from the calibration curve, according to0
0 1 2 3 4 5 6 7 8 9
CONCENTRATION
Fig. 5. Calibration curve of albendazole.
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Table 1
Linear regression equations generated from validation of albendazole and praziquantel: slope, intercept and coefficient of determination.
Analyte
Praziquantel Albendazole
Conc. (g/ml) Peak area (mV.s) Conc. (g/ml) Peak Area (mV.s)
0.05 0.060 Slope: 0.169 0.05 0.374 Slope: 1.064
0.1 0.071 0.1 0.442
1 0.257 1 1.550
2 0.388 Intercept: 0.060 2 2.440 Intercept: 0.358
3 0.580 3 3.601
4 0.728 4 4.470
5 0.903 5 5.770
6 1.069 r2: 0.999 6 6.712 r2: 0.999
7 1.244 7 7.814
8 1.427 8 8.888
Table 2
Spectral and statistical data for determination of albendazole and praziquantel by proposed RP-HPLC method.
Analyte
Praziquantel Albendazole
Absorption maxima, λ (nm) 225 Absorption maxima, λ (nm) 225
Linearity range (g/ml) 0.05–8 Linearity range (g/ml) 0.05–8
Coefficient of determination (r2) 0.999 Coefficient of determination (r2) 0.9991
Regression equation (Ya) Y = 0.169x + 0.060 Regression equation (Ya) Y = 1.064x + 0.358
Slope (b) 0.169 Slope (b) 1.064
Intercept (a) 0.060 Intercept (a) 0.358
Limit of detection, LOD (g/ml) 0.0167 Limit of detection, LOD (g/ml) 0.0167
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a Y = mx + c, where x is the concentration (g/ml).
.2.3.  Precision
The relative standard deviation was found to be <2.0%or both albendazole and praziquantel, indicating satis-
actory precision (Table 3). The intermediate precision
f the expected results is expressed as a percentage.
able 3a
ntra-day (n = 3) precision.
nalyte
lbendazole P
onc.
g/ml)
Conc. found at
4.5 (g/ml)
Avg.
(g/ml)
S.D % RSD C
(
.05 0.049
0.0496 0.0005 1.179
0
.05 0.0501 0
.05 0.0499 0
 3.914
3.928 0.063 1.610
4
 3.874 4
 3.998 4
 7.975
7.987 0.105 1.315
8
 8.098 8
 7.80 8
a % RSD = SD/mean × 100.Limit of quantitation, LOQ (g/ml) 0.05
3.2.4.  Accuracy
The mean recovery of praziquantel and albenda-zole was found to be in the range 100.81–100.92%
and 99.71–100.86%, respectively, within the accept-
able limits at 80%, 100% and 120% (Table 4a) and
raziquantel
onc.
g/ml)
Conc. found at
6.38 (g/ml)
Avg.
(g/ml)
S.D % RSDa
.05 0.499
0.050 0.0007 1.377.05 0.051
.05 0.049
 3.995
4.031 0.051 1.277 4.09
 4.008
 7.944
7.966 0.075 0.941 8.05
 7.905
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Table 3b
Inter-day (n = 3) precision.
Analyte
Albendazole Praziquantel
Conc.
(g/ml)
Conc. found at
4.5 (g/ml)
Avg.
(g/ml)
S.D % RSD Conc.
(g/ml)
Conc. found at
6.38 (g/ml)
Avg.
(g/ml)
S.D % RSDa
0.05 0.051
0.052 0.0009 1.82
0.05 0.052
0.051 0.0009 1.8570.05 0.052 0.05 0.050
0.05 0.051 0.05 0.051
4 4.104
4.18 0.078 1.880
4 4.115
4.147 0.061 1.4774 4.259 4 4.109
4 4.206 4 4.218
8 8.299
8.142 0.140 1.722
8 8.104
8.106 0.103 1.2778 8.098 8 8.211
8 8.029 8 8.004
a % RSD = SD/mean × 100.
Table 3c
Repeatability.
Analyte
Albendazole Praziquantel
Conc.
(g/ml)
Conc. found at
4.5 (g/ml)
Avg.
(g/ml)
S.D % RSD Conc.
(g/ml)
Conc. found at
6.38 (g/ml)
Avg.
(g/ml)
S.D % RSDa
4 3.994
4.039 0.058 1.44
4 4.115
4.055 0.054 1.34
4 3.974 4 4.109
4 3.998 4 4.018
4 4.104 4 3.995
4 4.059 4 4.09
44 4.106 
a % RSD = SD/mean × 100.
98.33–100.66% and 98.46–100.73% within the accept-
able limits at 50%, 100% and 150% (Table 4b).3.2.5. Speciﬁcity
Interference was found to be 100.81–100.92% for
albendazole and 100.39–100.89% for praziquantel,
Fig. 6. UV spectra of ALZ & PRQ with blank (methanol) (6 g/ml). 4.008
which is within the acceptable limit. Hence the excipients
do not interfere with estimates of drug concentrations
(Table 5).
3.2.6. Robustness
The retention times of the analytes did not change
significantly when the flow rate, mobile phase ratio and
pH were changed. The percentage recovery and rela-
tive standard deviation were within the limits for both
albendazole and praziquantel (Tables 6 and 7).
3.2.7. Sample  stock  solutions  for  assay
Ten tablets powdered equivalent were mixed in a ratio
of 300 mg albendazole: 25 mg praziquantel. A quantity
of this synthetic mixture powder equivalent to 65 mg
was taken up in a 100-ml volumetric flask, and diluent
was added up to the mark. The solution was sonicated
for 5 min. This solution was further diluted to obtain
a concentration of 12 g/ml albendazole and 5 g/ml
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Table 4a
Accuracy.
Analyte % Added Constant amount
addeda (g/ml)
Amount addedb
(g/ml)
Total amount
foundc (g/ml)
Amount foundd
(g/ml)
% Recoverye Average %
recovery
% RSD
PRZ (3 g/ml) 80 3 2.4 5.391 2.391 99.65
99.95 0.26380 3 2.4 5.403 2.403 100.13
80 3 2.4 5.401 2.401 100.08
100 3 3 5.958 2.958 98.63
99.38 0.903100 3 3 5.974 2.974 99.14
100 3 3 6.011 3.011 100.37
120 3 3.6 6.603 3.603 100.09
100.09 0.499120 3 3.6 6.582 3.582 99.50
120 3 3.6 6.617 3.617 100.49
ABZ (3 g/ml) 80 3 2.4 5.374 2.374 98.93
99.71 0.86080 3 2.4 5.390 2.390 99.58
80 3 2.4 5.415 2.415 100.63
100 3 3 6.025 3.025 100.84
100.86 0.832100 3 3 6.00 3.000 100.02
100 3 3 6.051 3.051 101.70
120 3 3.6 6.590 3.590 99.72
99.72 1.133120 3 3.6 6.635 3.635 100.98
120 3 3.6 6.671 3.6 101.97
a Preanalyzed sample found to be 3 g/ml.
b Pure drug added.
c Total concentration found i.e. c = a + b.
d Amount found i.e. d = c − a.
e % Recovery of ABZ or PRQ = ABZ or PRQ recovery (g/ml)/ABZ or PRQ input (g/ml) × 100 OR d/b × 100.
Table 4b
Accuracy.
Analyte % Added Constant amount
addeda (g/ml)
Amount addedb
(g/ml)
Total amount
foundc (g/ml)
Amount foundd
(g/ml)
% Recoverye Average %
recovery
% RSD
PRZ (3 g/ml) 50 3 1.5 4.486 1.486 99.06
99.62 0.48450 3 1.5 4.498 1.498 99.86
50 3 1.5 4.499 1.499 99.93
100 3 3 5.950 2.950 98.33
99.55 0.011100 3 3 5.990 2.990 99.66
100 3 3 6.020 3.020 100.66
150 3 4.5 7.480 4.480 99.55
99.55 0.007150 3 4.5 7.459 4.459 99.08
150 3 4.5 7.528 4.528 100.62
ABZ (3 g/ml) 50 3 1.5 4.516 1.516 101.06
100.33 0.61750 3 1.5 4.501 1.501 100.06
50 3 1.5 4.499 1.499 99.93
100 3 3 6.012 3.012 100.4
99.6 0.010100 3 3 5.998 2.998 99.93
100 3 3 5.954 2.954 98.46
150 3 4.5 7.501 4.501 100.02
100.02 0.003150 3 4.5 7.521 4.521 100.46
150 3 4.5 7.533 4.533 100.73
a Preanalyzed sample found to be 3 g/ml.
b Pure drug added.
c Total concentration found i.e. c = a + b.
d Amount found i.e. d = c − a.
e % Recovery of ABZ or PRQ = ABZ or PRQ recovery (g/ml)/ABZ or PRQ input (g/ml) × 100 OR d/b × 100.
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Table 5
Specificity.
Analyte % Added Excipient amount
added (mg)
Conc. founda
(g/ml)
% Recoveryb Avg. % recovery S.D % RSD
PRQ (10 mg) 50 5 3.008 100.28
100.89 0.563 0.55850 5 3.041 101.39
50 5 3.030 101.00
100 10 2.966 98.87
100.39 1.534 1.528100 10 3.058 101.94
100 10 3.010 100.36
150 15 2.995 99.84
100.74 0.791 0.78150 15 3.032 101.08
150 15 3.035 101.31
ABZ (10 mg) 50 5 3.039 101.24
100.92 0.363 0.36050 5 3.029 100.99
50 5 3.015 100.53
100 10 3.043 101.46
100.81 0.759 0.753100 10 2.999 99.97
100 10 3.030 101.00
150 15 3.050 101.71
100.90 0.716 0.71150 15 3.051 100.33
150 15 3.020 100.67
a The final dilution was made to 3 g/ml and analyzed for % recovery.
b % Recovery of ABZ or PRQ = ABZ or PRQ recovery (g/ml)/ABZ or PRQ input (g/ml) × 100.
Table 6
Determination of robustness for ABZ.
Sample I.D. Analytical condition ABZ input (mg) ABZ Rec. (mg) ABZ Rec. (%)a Mean Rec. ABZ (%) S.D. % RSD
Set-1 Flow rate: 1.02 ml/min
10 9.92 99.2
99.95 1.09 1.093
Mobile phase pH: 3.2
Mobile phase ratio: 60:40
Column: Enable
Set-2 Flow rate: 0.98 ml/min
10 10.05 100.5
Mobile phase pH: 3.2
Mobile phase ratio: 60:40
Column: Enable
Set-3 Flow rate: 1 ml/min
10 9.99 99.9
Mobile phase pH: 3.3
Mobile phase ratio: 60:40
Column: Enable
Set-4 Flow rate: 1 ml/min
10 10.08 100.8
Mobile phase pH: 3.1
Mobile phase ratio: 60:40
Column: Enable
Set-5 Flow rate: 1 ml/min
10 9.82 98.2
Mobile phase pH: 3.2
Mobile phase ratio: 58:42
Column: Enable
Set-6 Flow rate: 1 ml/min
10 10.11 101.1
Mobile phase pH: 3.2
Mobile phase ratio: 62:38
Column: Enable
a % Recovery of ABZ = ABZ recovery (mg)/ABZ input (mg) × 100.
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Table 7
Determination of robustness for PRQ.
Sample I.D. Analytical condition PRQ input (mg) PRQ Rec. (mg) PRQ Rec. (%)a Mean Rec. PRQ (%) S.D. % RSD
Set-1 Flow rate: 1.02 ml/min
10 9.85 98.5
100.28 1.123 1.12
Mobile phase pH: 3.2
Mobile phase ratio: 60:40
Column: Enable
Set-2 Flow rate: 0.98 ml/min
10 10.15 101.5
Mobile phase pH: 3.2
Mobile phase ratio: 60:40
Column: Enable
Set-3 Flow rate: 1 ml/min
10 10.02 100.2
Mobile phase pH: 3.3
Mobile phase ratio: 60:40
Column: Enable
Set-4 Flow rate: 1 ml/min
10 10.01 101
Mobile phase pH: 3.1
Mobile phase ratio: 60:40
Column: Enable
Set-5 Flow rate: 1 ml/min
10 9.95 99.5
Mobile phase pH: 3.2
Mobile phase ratio: 58:42
Column: Enable
Set-6 Flow rate: 1 ml/min
10 10.10 101.0
Mobile phase pH: 3.2
Mobile phase ratio: 62:38
Column: Enable
F
Sa % Recovery of PRQ = PRQ recovery (mg)/PRQ input (mg) × 100.
Fig. 7. Chromatogram of albendazole (4.533), praziquantel (6.39) a
ig. 8. Chromatogram of Albendazole and Praziquantel assay containing 6 
tandard (IS) (7.873).nd simvastatin as Intrnal Standard (I.S.) (7.873) (8.0 g/ml).
gm/ml of ABZ & 0.5 g/ml of PRQ with simvastatin as an Internal
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Table 8
Determination of % assay for ABZ & PRQ.
Synthetic mixture Drug Label claim
mg/tablet
Conc. estimated
(mg)
Mean conc.
estimated (mg)
% Assay (w/w)±a % RSDb
ABZ + PRQ PRQ 25 mg 25.287 25.044 99.77 ± 0.014 0.24
25.191
24.762
24.999
25.191
24.833
ABZ 300 mg 298.36 299.32 100.17 ± 0.0042 0.85
298.89
298.96
299.44
300.2
300.06
a % Recovery of ABZ or PRQ = ABZ or PRQ recovery (mg)/ABZ or PRQ input (mg) × 100 ± SD.
b % RSD = SD/mean × 100.
Table 9
System suitability parameters for ABZ & PRQ.
S. no. Parameters ABZ (min) PRQ (min)
1 Retention time, Rt (min) 4.5 min 6.39 min
2 Capacity factor (k) 4.468 6.6875
3 Separation factor (α) 1.496 1.496
4 Theoretical plates (USP) 3388.762 9682.56
5 HETP (mm)
6 Resolution (Rs) 
praziquantel. The results are summarized in Table 8, and
the chromatogram is shown in Fig. 8.
3.2.8.  System  suitability
The system suitability test is an integral part of
chromatographic analysis. It is used to verify that the
resolution and reproducibility of the system are adequate
for the analysis. A system suitability test according to
the United States Pharmacopeial Convention was per-
formed on chromatograms obtained for standard and test
solutions to check differences in the above-mentioned
parameters. The results obtained with six replicate
injections of the standard solution are summarized in
Table 9.
4.  Conclusions
An HPLC method for albendazole and praziquantel
has been developed, which is simple, precise and selec-
tive for simultaneous determination of the two drugs in
bulk and in synthetic mixtures. It can be used for process
control of bulk drug and formulated products in ordinary
laboratories and in the pharmaceutical industry.0.0738 0.0258
3.9426 7.0950
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